Tags

Type your tag names separated by a space and hit enter

Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients.
Hypertension. 2004 Sep; 44(3):294-9.H

Abstract

We assessed the effects of angiotensin-converting enzyme (ACE) inhibition on survival and cardiorenal outcomes in a consecutive cohort of Chinese type 2 diabetic patients with varying degree of albuminuria, ranging from normoalbuminuria to macroalbuminuria. A total of 3773 consecutive Chinese type 2 diabetic patients were followed prospectively for a mean period of 35.8 months. Clinical end points included all-cause mortality, with cardiovascular end point defined as first hospitalization because of ischemic heart disease, congestive heart failure, revascularization procedures, or cerebrovascular accident as well as renal end point defined as dialysis, doubling of baseline plasma creatinine, or plasma creatinine > or =500 micromol/L. The use of ACE inhibitor was 26.3% in normoalbuminuric (NA), 70.1% in microalbuminuric (MI), and 82.6% in macroalbuminuric (MA) groups. Albuminuria was a major predictor for all-cause mortality with 4-fold difference between NA and MA patients. The 7-year cumulative mortality rate was 7.1%, 10.8%, and 21.7% in the NA, MI, and MA groups, respectively. The use of ACE inhibition was associated with significant reduction of mortality (hazard ratio 0.41 and 95% confidence interval, 0.29, 0.58) in the entire group and was most evident in high-risk patients who had cardiorenal complications or retinopathy at baseline for all albuminuric groups (NA 0.76 [0.31,1.87]; MI 0.32 [0.16, 0.65]; and MA 0.20 [0.13, 0.33]). The prognostic value of albuminuria for death in type 2 diabetes and the beneficial effects of ACE inhibitors in Chinese type 2 diabetic patients with micro- or macroalbuminuria has been confirmed. The effects of ACE inhibitors in type 2 diabetic patients with normoalbuminuria require further evaluation.

Authors+Show Affiliations

Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong. wingyeeso@cuhk.edu.hkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15249544

Citation

So, Wing Yee, et al. "Effect of Angiotensin-converting Enzyme Inhibition On Survival in 3773 Chinese Type 2 Diabetic Patients." Hypertension (Dallas, Tex. : 1979), vol. 44, no. 3, 2004, pp. 294-9.
So WY, Ozaki R, Chan NN, et al. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. Hypertension. 2004;44(3):294-9.
So, W. Y., Ozaki, R., Chan, N. N., Tong, P. C., Ho, C. S., Lam, C. W., Ko, G. T., Chow, C. C., Chan, W. B., Ma, R. C., & Chan, J. C. (2004). Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. Hypertension (Dallas, Tex. : 1979), 44(3), 294-9.
So WY, et al. Effect of Angiotensin-converting Enzyme Inhibition On Survival in 3773 Chinese Type 2 Diabetic Patients. Hypertension. 2004;44(3):294-9. PubMed PMID: 15249544.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients. AU - So,Wing Yee, AU - Ozaki,Risa, AU - Chan,Norman N, AU - Tong,Peter C Y, AU - Ho,Chung Shun, AU - Lam,Christopher W K, AU - Ko,Gary T C, AU - Chow,Chun Chung, AU - Chan,Wing Bun, AU - Ma,Ronald C W, AU - Chan,Juliana C N, Y1 - 2004/07/12/ PY - 2004/7/14/pubmed PY - 2005/3/25/medline PY - 2004/7/14/entrez SP - 294 EP - 9 JF - Hypertension (Dallas, Tex. : 1979) JO - Hypertension VL - 44 IS - 3 N2 - We assessed the effects of angiotensin-converting enzyme (ACE) inhibition on survival and cardiorenal outcomes in a consecutive cohort of Chinese type 2 diabetic patients with varying degree of albuminuria, ranging from normoalbuminuria to macroalbuminuria. A total of 3773 consecutive Chinese type 2 diabetic patients were followed prospectively for a mean period of 35.8 months. Clinical end points included all-cause mortality, with cardiovascular end point defined as first hospitalization because of ischemic heart disease, congestive heart failure, revascularization procedures, or cerebrovascular accident as well as renal end point defined as dialysis, doubling of baseline plasma creatinine, or plasma creatinine > or =500 micromol/L. The use of ACE inhibitor was 26.3% in normoalbuminuric (NA), 70.1% in microalbuminuric (MI), and 82.6% in macroalbuminuric (MA) groups. Albuminuria was a major predictor for all-cause mortality with 4-fold difference between NA and MA patients. The 7-year cumulative mortality rate was 7.1%, 10.8%, and 21.7% in the NA, MI, and MA groups, respectively. The use of ACE inhibition was associated with significant reduction of mortality (hazard ratio 0.41 and 95% confidence interval, 0.29, 0.58) in the entire group and was most evident in high-risk patients who had cardiorenal complications or retinopathy at baseline for all albuminuric groups (NA 0.76 [0.31,1.87]; MI 0.32 [0.16, 0.65]; and MA 0.20 [0.13, 0.33]). The prognostic value of albuminuria for death in type 2 diabetes and the beneficial effects of ACE inhibitors in Chinese type 2 diabetic patients with micro- or macroalbuminuria has been confirmed. The effects of ACE inhibitors in type 2 diabetic patients with normoalbuminuria require further evaluation. SN - 1524-4563 UR - https://www.unboundmedicine.com/medline/citation/15249544/Effect_of_angiotensin_converting_enzyme_inhibition_on_survival_in_3773_Chinese_type_2_diabetic_patients_ L2 - https://www.ahajournals.org/doi/10.1161/01.HYP.0000137192.19577.c3?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -